Findings from Osaka Rosai Hospital in the Area of Immunotherapy Reported (The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers)
By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Current study results on Biotechnology have been published. According to news reporting out of Osaka, Japan, by NewsRx editors, research stated, "Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis and the eukaryotic elongation factor 2 (eEF2) was identified as an antigen that was recognized by IgG autoantibody in sera from a group of patients with head and neck squamous cell carcinoma (HNSCC) or colon cancer."
Our news journalists obtained a quote from the research from Osaka Rosai Hospital, "Enzyme-linked immunosorbent assay showed that serum eEF2 IgG Ab levels were significantly higher in colorectal and gastric cancer patients compared to healthy individuals. Immunohistochemistry experiments showed that the eEF2 protein was overexpressed in the majority of lung, esophageal, pancreatic, breast and prostate cancers, HNSCC, glioblastoma multiforme and non-Hodgkin's lymphoma (NHL). Knockdown of eEF2 by short hairpin RNA (shRNA) significantly inhibited the growth in four eEF2-expressing cell lines, PC14 lung cancer, PCI6 pancreatic cancer, HT1080 fibrosarcoma and A172 glioblastoma cells, but not in eEF2-undetectable MCF7 cells. Furthermore, eEF2-derived 9-mer peptides, EF786 (eEF2 786-794 aa) and EF292 (eEF2 292-300 aa), elicited cytotoxic T lymphocyte (CTL) responses in peripheral blood mononuclear cells (PBMCs) from an HLA-A*24:02- and an HLA-A*02:01-positive healthy donor, respectively, in an HLA-A-restricted manner. These results indicated that the eEF2 gene is overexpressed in the majority of several types of cancers and plays an oncogenic role in cancer cell growth."
According to the news editors, the research concluded: "Moreover, the eEF2 gene product is immunogenic and a promising target molecule of cancer immunotherapy for several types of cancers."
For more information on this research see: The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers. International Journal of Oncology, 2014;44(5):1461-1469. International Journal of Oncology can be contacted at: Spandidos Publ Ltd, Pob 18179, Athens, 116 10, Greece (see also Biotechnology).
Our news journalists report that additional information may be obtained by contacting Y. Oji, Osaka Rosai Hosp, Dept. of Surg, Osaka, Japan. Additional authors for this research include N. Tatsumi, M. Fukuda, S.I. Nakatsuka, S. Aoyagi, E. Hirata, I. Nanchi, F. Fujiki, H. Nakajima, Y. Yamamoto, S. Shibata, M. Nakamura, K. Hasegawa, S. Takagi, I. Fukuda, T. Hoshikawa, Y. Murakami, M. Mori, M. Inoue, T. Naka and To.
Keywords for this news article include: Osaka, Japan, Asia, Biotechnology, Cancer, Immunomodulation, Immunotherapy, Oncology, Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC